These are the stocks posting the largest moves before the bell.Market Insiderread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
Ross played down the prospect of an agreement being reached at the G-20 meeting in Osaka on June 28-29.Paris Airshowread more
"That's my view. They'll cut preemptively in June. That is to say Wednesday," says the Grant's Interest Rate Observer newsletter editor.Economyread more
Boeing is scrambling to restore confidence in the 737 Max from regulators, customers and the flying public.Paris Airshowread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
Heavy rains caused unprecedented delays in planting this year and contributed to record floods across the central United States.Agricultureread more
Here are the biggest calls on Wall Street on MondayInvestingread more
In a rare downgrade for the stock, Imperial Capital lowered its rating for Disney to in-line from outperform and maintained its target price of $147.Investingread more
GM CEO Mary Barra promised the automaker would launch 20 models of electric cars by 2023, beginning early this year. That plan may stall. A slowdown in China, a ratcheting up...Evolveread more
Senior economists from both political parties say a rate cut may not work that smoothly even if the Fed says yes. And that poses risks to America's decade-long recovery as the...Politicsread more
Health care and biotech stocks fell sharply after President-elect Donald Trump attacked the industry during his press conference Wednesday.
"We have to get our drug industry coming back. Our drug industry has been disastrous, they're leaving left and right. They supply our drugs but they don't make them here, to a large extent, " Trump said.
"And the other thing we have to do is create new bidding procedures for the drug industry, because they're getting away with murder, " he said.
The iShares Nasdaq Biotechnology ETF (IBB) briefly fell more than 2.5 percent, tracking for its first negative day of 2017. The health care SPDR (XLV) declined around .96 percent, with Endo International falling around 8.6 percent, Perrigo down more than 6 percent and Mallinckrodt down more than 7 percent.
Health care dropped more than 1.5 percent as the worst performer in the , with the pharmaceuticals sub-sector down more than 1.5 percent and the biotechnology sub-sector off nearly 3 percent.